Autopsy report · NCT03734887
Social Engagement Strategies to Improve Medication Adherence
Cause of deathStaffing, sites or logistics, also slow enrollment
“Inability to complete enrollment caused by COVID-19 and underpowered to conduct analysis”
Life of this trial
- Registered 1 year before it started.
- Ran for about 2 years 8 months before it stopped.
- 43 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Conditions
- Diabetes; Atherosclerosis Cardiovascular Disease; Congestive Heart Failure; Poor Medication Adherence
- Interventions
- Social Network Feedback; Private Feedback
- Participants
- 43
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
“Due to enrollment difficulties compounded by the COVID pandemic.” - Study of Latiglutenase in T1D/CD Patients
“Covid-19 interruptions and enrollment challenges” - Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
“Enrollment was affected due to the COVID-19 pandemic” - Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.
“Enrollment slower than anticipated and interrupted by COVID-19 pandemic” - Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis
“COVID-19 pandemic, unable to recruit and conduct study procedures per state, local, and university policies.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.